Uzzan, Mathieu http://orcid.org/0000-0002-7761-2879
Martin, Jerome C. http://orcid.org/0000-0003-0068-8776
Mesin, Luka
Livanos, Alexandra E.
Castro-Dopico, Tomas http://orcid.org/0000-0002-6964-5478
Huang, Ruiqi
Petralia, Francesca
Magri, Giuliana http://orcid.org/0000-0002-0163-3542
Kumar, Shashi
Zhao, Qing
Rosenstein, Adam K.
Tokuyama, Minami http://orcid.org/0000-0001-6488-9687
Sharma, Keshav
Ungaro, Ryan
Kosoy, Roman
Jha, Divya http://orcid.org/0000-0002-5038-241X
Fischer, Jeremy http://orcid.org/0000-0003-0001-4384
Singh, Harpriya
Keir, Mary E. http://orcid.org/0000-0002-0637-4092
Ramamoorthi, Nandhini
O’Gorman, William E.
Cohen, Benjamin L.
Rahman, Adeeb
Cossarini, Francesca http://orcid.org/0000-0002-8793-5241
Seki, Akihiro
Leyre, Louise
Vaquero, Sonia Tejedor http://orcid.org/0000-0003-2873-4981
Gurunathan, Sakteesh
Grasset, Emilie K. http://orcid.org/0000-0002-9592-1640
Losic, Bojan
Dubinsky, Marla
Greenstein, Alexander J.
Gottlieb, Zoe
Legnani, Peter
George, James
Irizar, Haritz
Stojmirovic, Aleksandar
Brodmerkel, Carrie
Kasarkis, Andrew
Sands, Bruce E.
Furtado, Glaucia
Lira, Sergio A. http://orcid.org/0000-0002-6742-3089
Tuong, Zewen K.
Ko, Huaibin M. http://orcid.org/0000-0003-1062-2383
Cerutti, Andrea
Elson, Charles O.
Clatworthy, Menna R.
Merad, Miriam http://orcid.org/0000-0002-4481-7827
Suárez-Fariñas, Mayte
Argmann, Carmen http://orcid.org/0000-0002-1110-8012
Hackney, Jason A. http://orcid.org/0000-0002-5922-563X
Victora, Gabriel D. http://orcid.org/0000-0001-8807-348X
Randolph, Gwendalyn J. http://orcid.org/0000-0001-9045-1195
Kenigsberg, Ephraim
Colombel, Jean Frederic
Mehandru, Saurabh http://orcid.org/0000-0001-9781-2969
Article History
Received: 16 February 2020
Accepted: 4 January 2022
First Online: 21 February 2022
Competing interests
: S.M. and J.F.C. have an unrestricted, investigator-initiated grant from Takeda Pharmaceuticals to examine novel homing mechanisms to the gastrointestinal tract. R.C.U. has served as an advisory board member or consultant for Eli Lilly, Janssen, Pfizer and Takeda. Mount Sinai coauthors (from Genetics and Genomics, Icahn Institute for Data Science and Genomic Technology, Human Immune Monitoring Center, Population Health Science and Policy, Division of Gastroenterology, Pediatric GI and Hepatology, Susan and Leonard Feinstein IBD Clinical Center at the Icahn School of Medicine at Mount Sinai) were partially funded as part of the research alliance between Janssen Biotech and the Icahn School of Medicine at Mount Sinai. J.P. and C.B. are employees of Janssen Research and Development, and J.R.F. is a former employee of Janssen Research and Development and is currently employed at Alnylam Pharmaceuticals. M.K., N.R., W.O. and J.H. are all employees of Genentech. M.D. is a consultant for Janssen, Abbvie, Arena, Bristol Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen, Pfizer, Prometheus Labs and Takeda. C.E. has received research support from Merck. R.U. has served as an advisory board member or consultant for AbbVie, Bristol Meyers Squibb, Janssen, Pfizer and Takeda and has received research support from AbbVie, Boehringer Ingelheim, Eli Lilly and Pfizer. J.F.C. reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Ferring Pharmaceuticals, Shire and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, GlaxoSmithKline, Geneva, Iterative Scopes, Janssen Pharmaceuticals, Kaleido Biosciences, Landos, Otsuka, Pfizer, Prometheus, Sanofi, Takeda and TiGenix; and holding stock options in Intestinal Biotech Development. B.L.C. receives the following financial support: advisory boards and consultant for Abbvie, Celgene/Bristol Myers Squibb, Eli Lilly, Pfizer, Sublimity Therapeutics, Takeda and TARGET RWE; CME companies: Cornerstones and Vindico; speaking fees: Abbvie; and educational grant: Pfizer. B.S. discloses research grants from Takeda, Pfizer, Theravance Biopharma R&D and Janssen; consulting fees from 4D Pharma, Abivax, Abbvie, Alimentiv, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Bacainn Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Capella Bioscience, Celgene, Celltrion Healthcare, ClostraBio, Enthera, F. Hoffmann-La Roche, Ferring, Galapagos, Gilead, GlaxoSmithKline, GossamerBio, Immunic, Index Pharmaceuticals, Innovation Pharmaceuticals, Ironwood Pharmaceuticals, Janssen, Kaleido, Kallyope, Eli Lilly, MiroBio, Morphic Therapeutic, Oppilan Pharma, OSE Immunotherapeutics, Otsuka, Palatin Technologies, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, Redhill Biopharma, Rheos Medicines, Salix Pharmaceuticals, Seres Therapeutics, Shire, Sienna Biopharmaceuticals, Sun Pharma, Surrozen, Takeda, Target PharmaSolutions, Teva Branded Pharmaceutical Products R&D, Thelium, Theravance Biopharma R&D, TLL Pharma, USWM Enterprises, Ventyx Biosciences, Viela Bio, Vivante Health and Vivelix Pharmaceuticals; and stock in Vivante Health and Ventyx Biosciences. All other authors declare no competing interests.